Product Information
XOFLUZA 40 MG TABLET is a brand product labeled by Genentech, Inc., priced at $161.9388 per EA under NDC 50242086001. Its NADAC has been published 250 times since Dec 22, 2021.
FDA first approved this application on Oct 24, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Genentech, Inc.NDC
50242086001
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BALOXAVIR MARBOXILApproval Type
New Drug (NDA)
FDA Application
NDA210854FDA Approved
10/24/2018
TE Code
AB
On Market Since
10/24/2018
Pharmacological Classes
Price Statistics
The NADAC for XOFLUZA 40 MG TABLET has been published 250 times since Dec 22, 2021, and over the history we have for it it has risen 14.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $161.9388 per EA |
|---|---|
| All-time high | $163.5863 (Jan 14, 2026) |
| All-time low | $141.8262 (Dec 22, 2021) |
| 52-week high | $163.5863 |
| 52-week low | $161.9388 |
| Median price | $152.7973 |
| Average price | $154.3495 |
| Largest weekly change | +3.0% (Jul 12, 2023) |
| Weeks tracked | 250 |
| Tracking since | Dec 22, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the BALOXAVIR MARBOXIL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Genentech, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
BALOXAVIR MARBOXIL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XOFLUZA 40 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for XOFLUZA 40 MG TABLET, manufactured by Genentech, Inc., is $161.9388 per EA (NDC 50242086001), effective Sep 30, 2026.
How has the price of XOFLUZA 40 MG TABLET changed over time?
Over the history we have for it, the NADAC for XOFLUZA 40 MG TABLET has risen 14.2%. It has been tracked across 250 weekly CMS publications since Dec 22, 2021.
What are the highest and lowest recorded NADAC prices for XOFLUZA 40 MG TABLET?
Since Dec 22, 2021, the NADAC for XOFLUZA 40 MG TABLET has ranged from a low of $141.8262 (Dec 22, 2021) to a high of $163.5863 (Jan 14, 2026), with a median of $152.7973 per EA.
Are there cheaper alternatives to XOFLUZA 40 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of XOFLUZA 40 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XOFLUZA 40 MG TABLET?
XOFLUZA 40 MG TABLET (NDC 50242086001) is labeled by Genentech, Inc., and CMS classifies it as a brand product.